new
strategi
prevent
treat
influenza
viru
infect
urgent
need
recent
discov
class
monoclon
antibodi
mab
neutral
unpreced
spectrum
influenza
viru
subtyp
may
potenti
futur
use
human
assess
efficaci
repres
novel
class
mab
oseltamivir
mice
show
singl
inject
mgkg
outperform
cours
treatment
oseltamivir
mgkgday
respect
prophylaxi
treatment
lethal
infect
result
justifi
preclin
evalu
broadli
neutral
mab
influenza
viru
prevent
treatment
influenza
viru
infect
unlik
effect
vaccin
avail
earli
stage
pandem
treatment
andor
prophylaxi
influenza
viru
infect
class
drug
current
avail
adamantan
neuraminidas
na
inhibitor
adamantan
amantadin
rimantadin
associ
toxic
rapid
emerg
drugresist
strain
compar
adamantan
licens
na
inhibitorszanamivir
relenza
oseltamivir
tamiflu
associ
littl
toxic
less
prone
select
resist
virus
nevertheless
emerg
resist
oseltamivir
treatment
report
refer
therein
furthermor
oseltamivirresist
virus
circul
major
contin
although
present
virus
suscept
zanamivir
result
increas
use
zanamivir
monotherapi
may
well
lead
develop
resist
consequ
urgent
need
develop
new
treatment
prophylact
therapeut
monoclon
antibodi
mab
attract
biolog
drug
given
exquisit
specif
low
toxic
develop
mab
prophylaxi
treatment
influenza
inhibit
lack
candid
broad
neutral
activ
result
viru
toler
genet
chang
immunodomin
epitop
howev
recent
discov
class
mab
abl
neutral
unpreced
spectrum
influenza
viru
subtyp
bind
highli
conserv
region
membraneproxim
stem
viral
hemagglutinin
hold
promis
futur
intervent
season
pandem
influenza
compar
prophylact
therapeut
efficaci
mab
repres
novel
class
antiinfluenza
viru
mab
lead
antivir
drug
oseltamivir
mous
model
lethal
infect
method
human
mab
describ
elsewher
irrelev
isotypematch
antibodi
use
control
antibodi
produc
cell
crucel
holland
oseltamivir
tamiflu
hoffmannla
roch
obtain
local
pharmaci
strain
origin
isol
child
respiratori
diseas
viru
passag
twice
mdck
cell
stock
log
median
tissu
cultur
infect
dose
tcid
ml
use
infect
mice
propag
embryon
egg
strain
obtain
american
type
cultur
collect
stock
log
tcid
ml
use
infect
mice
propag
embryon
egg
experi
approv
ethic
review
committe
central
veterinari
institut
commenc
accord
dutch
law
femal
specif
pathogenfre
balbc
mice
charl
river
laboratori
inocul
intranas
time
median
lethal
dose
log
tcid
log
tcid
surviv
weight
loss
clinic
sign
monitor
day
infect
clinic
sign
score
score
system
clinic
sign
rough
coat
rough
coat
less
reactiv
passiv
handl
rough
coat
roll
labor
breath
passiv
handl
rough
coat
roll
labor
breath
unrespons
anim
score
euthan
prophylact
experi
mgkg
administ
intraven
day
challeng
mgkg
oseltamivir
administ
per
os
daili
day
start
day
challeng
therapeut
experi
oseltamivir
administ
describ
day
day
start
day
infect
respect
surviv
time
viral
challeng
analyz
use
logrank
test
surviv
proport
analyz
use
fisher
exact
test
chang
bodi
weight
analyz
use
area
curv
auc
analysi
last
observ
bodi
weight
carri
forward
mous
die
euthan
experi
weight
per
mous
day
use
baselin
weight
chang
determin
rel
baselin
net
auc
compar
analysi
varianc
comparison
control
group
perform
posthoc
test
dunnett
adjust
multipl
comparison
clinic
score
analyz
use
genmod
procedur
sa
softwar
fit
model
repeat
measur
mice
subject
data
measur
ordin
scale
statist
analys
perform
use
sa
version
sa
institut
spss
version
spss
softwar
statist
signific
level
set
p
result
figur
show
prophylact
efficaci
mab
oseltamivir
lethal
challeng
anim
receiv
surviv
challeng
virus
without
show
sign
diseas
except
declin
bodi
weight
first
day
challeng
figur
contrast
control
anim
rapidli
show
sign
diseas
lost
weight
either
die
infect
euthan
within
week
either
challeng
one
oseltamivirtr
mice
surviv
challeng
figur
howev
contrast
mice
anim
lost
weight
compar
control
group
day
infect
start
regain
weight
figur
furp
thermor
oseltamivirtr
mice
show
sign
ill
begin
day
infect
start
recov
day
figur
similarli
treatment
oseltamivir
prevent
death
weight
loss
sign
diseas
challeng
mice
treat
oseltamivir
lost
weight
similarli
control
group
first
day
challeng
start
regain
weight
figur
loss
greater
group
treat
sign
diseas
observ
individu
p
anim
day
challeng
median
clinic
score
differ
significantli
group
day
figur
p
altern
median
clinic
score
group
like
explain
subject
assess
clinic
score
differ
observ
taken
togeth
data
indic
prophylact
administr
singl
intraven
inject
mgkg
effect
lethal
challeng
cours
treatment
oseltamivir
mgkgday
figur
show
therapeut
efficaci
mab
oseltamivir
lethal
challeng
treatment
four
day
challeng
prevent
initi
weight
loss
sign
diseas
howev
complet
prevent
mortal
anim
regain
initi
bodi
weight
end
experi
figur
accordingli
mice
start
recov
day
none
show
sign
diseas
day
onward
contrast
surviv
group
treat
mice
treat
oseltamivir
surviv
infect
mice
lost
signifp
p
icantli
weight
group
treat
median
clinic
score
signifip
p
cantli
higher
day
end
studi
day
survivor
show
respiratori
distress
p
day
regain
initi
bodi
weight
end
studi
although
prophylact
administr
fulli
protect
mice
lethal
challeng
anim
surviv
given
day
challeng
figur
nevertheless
surviv
time
group
significantli
longer
group
treat
oseltamivir
anim
die
within
day
challeng
howev
signific
differ
p
p
rel
weight
loss
group
p
p
clinic
score
differ
significantli
day
respect
figur
p
p
p
p
discuss
demonstr
singl
intraven
inject
mgkg
outperform
cours
treatment
oseltamivir
mgkgday
respect
prophylaxi
treatment
lethal
infect
mice
encourag
result
highli
stringent
model
justifi
preclin
evalu
altern
strategi
control
influenza
mgkg
dose
use
studi
base
previou
experi
mice
studi
need
assess
minim
plasma
concentr
mab
necessari
effect
prophylaxi
treatment
cours
treatment
oseltamivir
mgkgday
previous
shown
protect
lethal
challeng
mice
wherea
treatment
dose
low
mgkgday
even
mgkgday
shown
protect
mice
lethal
challeng
latter
studi
oseltamivir
administ
twiceaday
regimen
wherea
use
onceaday
regimen
howev
compar
efficaci
daili
administr
mgkg
oseltamivir
daili
administr
mgkg
lethal
ahongkong
infect
found
differ
data
shown
result
line
previous
report
data
show
signific
differ
efficaci
oseltamivir
mgkg
day
lethal
infect
mice
given
singl
dose
dose
h
apart
although
therapeut
administr
complet
prevent
death
due
partial
prevent
mortal
due
differ
like
explain
fact
onset
diseas
progress
death
rapid
challeng
latter
viru
median
clinic
score
moment
antibodi
administr
day
challeng
group
mice
challeng
respect
accordingli
median
surviv
time
control
group
challeng
shorter
control
group
challeng
vs
day
howev
fact
administr
p
p
mice
alreadi
lost
initi
bodi
weight
show
sever
respiratori
distress
still
partial
prevent
death
demonstr
fast
mode
action
featur
combin
rel
long
halflif
week
human
mab
produc
cell
make
human
mabbas
passiv
immunotherapi
viabl
option
treatment
prophylaxi
diseas
due
influenza
viru
infect
provid
compar
efficaci
obtain
human
econom
feasibl
dose
antibodi
